NeuroMetrix to Present at Rodman & Renshaw Annual Global Investment Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Sep. 5, 2012--
NeuroMetrix, Inc. (Nasdaq: NURO),
www.neurometrix.com,
a medical device company focused on the diagnosis and treatment of the
neurological complications of diabetes, today announced that Thomas T.
Higgins, Senior Vice President and Chief Financial Officer, is scheduled
to speak at the Rodman & Renshaw Annual
Global Investment Conference at
The Waldorf
Astoria, New York, NY on
September 9-11, 2012. Mr. Higgins
intends to provide an update on the Company’s business activities and on
its diabetes products including NC-stat
® DPNCheck
™,
a diagnostic test for systemic neuropathies such as diabetic peripheral
neuropathy (DPN), and the SENSUS
™ pain management device for
relief of chronic intractable pain.
NeuroMetrix's presentation is scheduled for Tuesday, September 11, 2012
at 4:30 PM (Eastern Daylight Time) in the North Foyer. A live audio
webcast will be available on the investor relations section of the
corporate website - www.neurometrix.com.
This webcast will be archived after the live event.
About NeuroMetrix
NeuroMetrix is an innovative medical device company that develops and
markets home use and point-of-care devices, associated consumables, and
support software for the treatment and management of diabetes and its
complications. The company is focused on nerve related complications of
diabetes, called diabetic neuropathies, which affect over 50% of people
with diabetes. If left untreated, diabetic neuropathies trigger foot
ulcers that may require amputation, cause disabling chronic pain, and
increase the risk of falling in the elderly. The annual cost of diabetic
neuropathies has been estimated at $14 billion in the United States. The
company’s products are used by physicians and other clinicians, in
retail health settings such as pharmacies, and by managed care
organizations to optimize patient care and reduce healthcare costs. The
company markets the NC-stat® DPNCheck™ device,
which is a rapid, accurate, and quantitative point-of-care test for
diabetic neuropathy. This product is used to detect diabetic neuropathy
at an early stage and to guide treatment. The company is in late stage
development of SENSUS™, a pain management device which
recently received Food and Drug Administration clearance. The company
has additional therapeutic products in its pipeline. For more
information, please visit http://www.neurometrix.com.
Source: NeuroMetrix
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
